Bayer Presents Latest Cardiovascular Research at HFSA

Oct. 8, 2026 – At the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, Bayer announced that latest research from cardiovascular programs would be presented in a late-breaking presentation along with five poster sessions. 

“The HFSA Annual Scientific Meeting is an ideal platform to raise awareness of the essential role that clinical trials play in advancing cardiovascular disease care,” said Robert Perkins, MD, Vice President CVR, U.S. Medical Affairs. “We look forward to sharing our science with the community and advancing the industry’s mission of potentially improving patient care.” 

Data from Bayer’s cardiovascular portfolio in heart failure and cardiac amyloidosis will be presented, including late-breaking data for investigational iodine 124 evuzamitide (I 124 evuzamitide) from a Phase III study in patients with suspected cardiac amyloidosis.

The HFSA cardiovascular presentations include:

Cardiac Amyloidosis 

• 124I-Evuzamitide amyloid-targeted PET/CT scan: Potential for detection of early cardiac amyloidosis in a prospective multicenter phase 3 study cohort 

Heart Failure 

• Factors Associated With Steroidal Mineralocorticoid Receptor Antagonist Use in Newly Diagnosed Heart Failure 

• Real-world Initiation And Non-persistence Of Steroidal Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure In The United States 

•  A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)  

• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF)  

•